Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Biosensors BioMatrix
Feature | Kamran Zamanian, Ph.D.

The interventional cardiology market includes, but is not limited to, drug-eluting stents, bare-metal stents ...

Home February 04, 2013
Home
News

January 30, 2013 — Coronary artery disease and peripheral artery disease are global health issues that affect millions ...

Home January 30, 2013
Home
Abbott Absorb bioresorbable stent
Feature

January 8, 2013 — Abbott announced the initiation of the ABSORB III clinical trial in patients in the United States. The ...

Home January 08, 2013
Home
News

November 7, 2012 — Micell Technologies Inc. announced positive data from two clinical studies of its investigational ...

Home November 07, 2012
Home
Feature

October 31, 2012 — Boston Scientific Corp. received CE mark approval for the Synergy everolimus-eluting platinum ...

Home October 31, 2012
Home
DESolve Nx Pivotal Trial Bioresorbable Coronary Stent Elixir Cath Lab
Feature

October 30, 2012 — Elixir Medical Corp. said enrollment is complete in its 120-patient, pivotal clinical trial ...

Home October 30, 2012
Home
Feature

October 19, 2012 — The 24th Transcatheter Cardiovascular Therapeutics (TCT) conference, sponsored by the Cardiovascular ...

Home October 19, 2012
Home
News

October 19, 2012 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices ...

Home October 19, 2012
Home
Abbott Bioabsorbable Stent  Absorb
Feature

September 28, 2012 — The world’s first drug-eluting bioabsorbable vascular scaffold has been launched and will ...

Home September 28, 2012
Home
Abbott bioresorbable Absorb stent BVS
Feature

September 26, 2012 — Abbott Vascular this week began its international launch of the Absorb coronary stent, the world's ...

Home September 26, 2012
Home
News

August 14, 2012 — The U.S. Food and Drug Administration (FDA) is hosting a public workshop that examines use of ...

Home August 14, 2012
Home
News

July 17, 2012 — Arterial Remodeling Technologies (ART) reported that they have achieved a medical milestone with its ...

Home July 17, 2012
Home
News

July 16, 2012 — Reva Medical Inc. announced it completed clinical enrollment with the ReZolve drug-eluting bioresorbable ...

Home July 16, 2012
Home
News

April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza self ...

Home April 16, 2012
Home
News

April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its ...

Home April 05, 2012
Home
Subscribe Now